WEARING A MASK IS STILL REQUIRED IN PATIENT AREAS AT SUNNYBROOK. READ OUR VISITOR GUIDELINES »

Cancer trials
Hospital  >  Care Programs  >  Odette Cancer Program  >  Clinical trials

Trial details

Clonal Hematopoiesis is a Risk Factor for Chemotherapy-Related Complications

To find out more about this trial and your cancer treatment options, please speak with your doctor.

Trial short name: CHIP

Official title: Clonal Hematopoiesis is a Risk Factor for Chemotherapy-Related Complications

Principal Investigator: Dr. Rena Buckstein

Cancer type: Blood Related
Cancer location: Lymphoma
Disease stage: Early Cancer
Trial phase: Other
Intervention: Other: Blood test

Registration #: NCT04053439

Trial description:
This study investigates whether CHIP in lymphoma patients is a risk factor for chemotherapy-related complications (low blood counts, infections, cardiac events, hospitalizations etc.). 'CHIP' stands for Clonal Hematopoiesis of Indeterminate Significance, which are mutations in bone marrow stem cells that give that population of cells a survival or 'clonal' advantage for growth. Patients with lymphoma who are older that 60 years of age, receiving chemotherapy treatment, and who meet certain other criteria may be able to participate. All patients participating in this study will receive an additional blood draw to test for CHIP. The results from this study may help physicians better understand why some people have difficulty with chemotherapy (in the short and long-term) while others do not.

Inclusion Criteria: • Diagnosis of a lymphoma (ex: diffuse large B cell lymphoma (DLBCL), follicular lymphoma, marginal zone lymphoma, small lymphocytic lymphoma/chronic lymphocytic leukemia, Hodgkin's lymphoma, peripheral T cell lymphoma, anaplastic large cell lymphoma, angioimmunoblastic lymphoma, hairy cell leukemia, Waldenstrom's macroglobulinemia, anaplastic large cell lymphoma, small lymphocytic lymphoma/chronic lymphocytic leukemia, and mantle cell lymphoma). • Commencing first or second-line cytotoxic chemotherapy for lymphoma with or without rituximab [ex: cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), cyclophosphamide, vincristine and prednisone (CVP), Fludarabine, fludarabine cyclophosphamide (FC), Bendamustine, cisplatin, cytarabine, dexamethasone (DHAP), etoposide, cytarabine, cisplatin, prednisone (ESHAP), gemcitabine, cisplatin and dexamethasone (GDP), Cladribine, Cyclophosphamide, Epirubicin, Vincristine, Prednisone (CEOP), dose-adjusted Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (DA-EPOCH)] Exclusion Criteria: • Pre-existing diagnosis of myeloid neoplasm • Circulating lymphocyte count > 10 x 109/L • Significant uncontrolled renal or hepatic impairment [>1.5 x upper limit of normal (ULN) bilirubin, >1.5 x ULN Alanine aminotransferase (ALT), >1.5 x ULN creatinine] • HIV • Active infection